USPTO serial 90690440
EIKON
Reviewed by CopyMark Law Group
Status 606
- Filing date
- Status date
- Registration date
- —
- Examiner
- FRUM MILONE, MARCIE R
- Law office
- INTENT TO USE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with EIKON?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Ilene B. Tannen
Ilene B. Tannen Jones Day250 Vesey StreetNew York, NY 10281-1047United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 042 | Pharmaceutical drug discovery and development services; Scientific and medical research, development and information services in the fields of pharmaceuticals, biopharmaceuticals, therapeutics, vaccines, diagnostics, and medicine discovery and development; Drug discovery and pharmaceutical development services for the pharmaceutical, biopharmaceutical, therapeutic, vaccine, diagnostic, and medicine industries; Providing temporary use of on-line non-downloadable software for tracking and measuring movement of proteins in living cells for drug discovery and development; Providing temporary use of on-line non-downloadable software for tracking and measuring movement of proteins in living cells for pharmaceutical, biopharmaceutical, therapeutic, vaccine, diagnostic, and medicine discovery and development services; Drug, pharmaceutical, biopharmaceutical, therapeutic, vaccine, diagnostic, and medicine research and development and testing; Research and development of new products in the fields of drugs, pharmaceuticals, biopharmaceuticals, therapeutics, vaccines, diagnostics, and medicines; Biomedical research and development services in the fields of cancer, immunological disorders, neuro-related disorders, cardio-vascular disorders, metabolic disorders, gastroenterology, dermatology, endocrinology, infectious diseases and ophthalmologic disorders; Medical and clinical research and pharmaceutical development services to discover and develop medicines and vaccines in the fields of cancer, immunological disorders, neuro-related disorders, cardio-vascular disorders, metabolic disorders, gastroenterology, dermatology, endocrinology, infectious diseases and ophthalmologic disorders; Research, development, analysis, testing and consulting services in the fields of biochemistry, biotechnology, medicines, diagnostics, vaccines and pharmaceuticals; Scientific, medical, biological, biotechnology, biomedical, pharmaceutical research, development, analysis and testing services in the fields of cancer, immunological disorders, neuro-related disorders, cardio-vascular disorders, metabolic disorders, gastroenterology, dermatology, endocrinology, infectious diseases and ophthalmologic disorders; Scientific laboratory services, namely, live cell imaging analysis; Custom design and development of cells, cell lines and assays; Biomedical research services using a platform of biological tools and techniques for use in scientific research, drug and vaccine discovery and development; Providing a website featuring information in the fields of drug discovery and development, biochemistry, biotechnology, medicines, diagnostics, and pharmaceuticals; Provision of scientific, medical, biotechnology, biomedical, vaccine and pharmaceutical information regarding drug discovery, pharmaceutical products, vaccines and clinical trials | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 31, 2025 | MAB6 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Oct 31, 2025 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Jun 25, 2025 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Jun 25, 2025 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jun 25, 2025 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Jun 25, 2025 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Jun 25, 2025 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Mar 27, 2025 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Mar 26, 2025 | EX5G | SOU EXTENSION 5 GRANTED | — |
| Jan 30, 2025 | EXT5 | SOU EXTENSION 5 FILED | — |
| Jan 30, 2025 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Sep 5, 2024 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Sep 5, 2024 | EX4G | SOU EXTENSION 4 GRANTED | — |
| Sep 5, 2024 | EXT4 | SOU EXTENSION 4 FILED | — |
| Sep 5, 2024 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Mar 5, 2024 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Mar 4, 2024 | EX3G | SOU EXTENSION 3 GRANTED | — |
| Mar 4, 2024 | EXT3 | SOU EXTENSION 3 FILED | — |
| Mar 4, 2024 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Sep 26, 2023 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Sep 22, 2023 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Sep 22, 2023 | EXT2 | SOU EXTENSION 2 FILED | — |
| Sep 22, 2023 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Mar 22, 2023 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Mar 20, 2023 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Mar 20, 2023 | EXT1 | SOU EXTENSION 1 FILED | — |
| Mar 20, 2023 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Sep 27, 2022 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Aug 2, 2022 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Aug 2, 2022 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jul 13, 2022 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jun 25, 2022 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jun 25, 2022 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Jun 25, 2022 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Jun 25, 2022 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Jun 25, 2022 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Jan 6, 2022 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 6, 2022 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 6, 2022 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 5, 2022 | DOCK | ASSIGNED TO EXAMINER | — |
| Sep 13, 2021 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Sep 13, 2021 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Sep 13, 2021 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Aug 6, 2021 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| May 7, 2021 | NWAP | NEW APPLICATION ENTERED | — |